Navigation Links
Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria
Date:9/17/2014

LA JOLLA, CASeptember 17, 2014Scientists at The Scripps Research Institute (TSRI) have devised a new antibiotic based on vancomycin that is powerfully effective against vancomycin-resistant strains of MRSA and other disease-causing bacteria.

The new vancomycin analog appears to have not one but two distinct mechanisms of anti-microbial action, against which bacteria probably cannot evolve resistance quickly.

"This is the prototype of analogues that once introduced will still be in clinical use a generation or maybe even two generations from now," said Dale L. Boger, the Richard and Alice Cramer Professor of Chemistry at TSRI.

The report by Boger and members of his laboratory was published recently online ahead of print by the Journal of the American Chemical Society.

Increasing Reports of Resistance

Vancomycin entered clinical use in 1958, five years after its isolation from microbes in a soil sample gathered by an American missionary in Borneo. For nearly six decades it has been useful against a wide range of bacteria, and it remains a standard weapon against methicillin-resistant Staphylococcus aureus (MRSA), a major cause of hospital-acquired infections. A compound closely related to vancomycin also has been widely used to protect livestock.

Since the late 1980s, there have been increasing reports of vancomycin resistance in classes of bacteria that usually succumb to the antibiotic, including MRSA. Although vancomycin remains useful, scientists have been looking for new drugs to replace it in casesoften life-threateningwhere it no longer can help patients.

The Boger laboratory has focused on inventing improved versions of vancomycin rather than entirely new compounds. "Vancomycin has lasted in clinical use for more than 50 years, in part because it isn't very vulnerable to antibiotic resistance," Boger said. "Our thought has been that if we find a vancomycin analog that addresses this current source of resistance we'll get another 50 years of use out of it."

Vancomycin works by binding to the building blocks of bacterial cell walls, in a way that prevents their proper assembly and leaves bacteria too leaky to live and replicate. The resistance comes from a single amino-acid alteration that some bacteria make to those building blocks, so that the antibiotic molecule can no longer get a firm grip. That drops vancomycin's potency by a factor of about 1,000.

'Incredibly Potent'

In 2012, Boger and his team reported making a vancomycin analoginformally termed vancomycin amidinewith a subtly altered binding pocket that fastens about equally well to the original and resistant sites on bacterial cell wall subunits. To get the precise structural modification they needed, they had to come up with a method for the "total synthesis" of this vancomycin-based compounda controlled, step-by-step construction using organic chemistry reactions in the lab, rather than a natural enzyme-mediated production within cells.

"Years of work in this lab culminated in a total synthesis strategy that not only allowed us access to this target compound, but also gave us the ability to perform almost any other chemical modification of vancomycin that we wished," said Akinori Okano, first author of the new report, who is an assistant professor of chemistry at TSRI.

Vancomycin amidine turned out to have acceptable level of activity against vancomycin-resistant and -sensitive bacteria, yet there was room for improvement. Thus in the new study, Okano, Boger and their colleagues used their vancomycin synthesis methods to add an additional feature to the moleculea peripheral chlorobiphenyl (CBP), long known as a general booster of vancomycin's potency.

"To our delight, the combination of these modifications led to an incredibly potent molecule, well beyond anything we had expected," said Okano.

In lab dish tests, the new vancomycin analog proved highly effective against the usual vancomycin-sensitive bacteria as well as vancomycin-resistant MRSA and enterococcal bacteria.

The tests also suggested that the CBP modification, whose boost to potency has been thought to come from some broad enhancement of vancomycin's activity, might in fact work via its own distinct attack on bacterial cell wall synthesis.

"This is probably the clearest depiction to date of the fact that for the CBP derivatives there must be a second mechanism of action, independent of vancomycin's main mechanism of action," Boger said. "[Such analogs] are likely to display especially durable antibiotic activitythat is, they won't be prone to rapidly acquired clinical resistance."

Boger and his colleagues now will try to optimize the synthesis process for the new analog, to provide quantities suitable for preclinical testing in animals.


'/>"/>

Contact: Madeline McCurry Schmidt
madms@scripps.edu
858-784-9254
Scripps Research Institute
@scrippsresearch
Source:Eurekalert  

Related medicine news :

1. Scripps Research scientists show how memory B cells stay in class to fight different infections
2. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
3. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
4. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
5. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
6. Scripps Research Institute receives $20 million to shed light on HIV drug resistance
7. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
8. 2 Scripps Research Institute scientists honored by American Chemical Society
9. Scripps Research Institute study points to potential new therapies for cancer and other diseases
10. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
11. Scripps Florida scientist awarded $2.5 million to study inner workings of memory formation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria
(Date:8/17/2018)... ... August 17, 2018 , ... An August 7 article in UAB ... low birth weight could be significantly reduced if women were more vigorously encouraged to ... which a very large number of pregnant women suffer from to some extent. West ...
(Date:8/15/2018)... ... August 15, 2018 , ... Many people might desire ... to achieve it. That’s where a great new option comes in: Injectable filler, which ... Sonoa Au, MD of Advanced Dermatology P.C. , An increasingly popular option ...
(Date:8/15/2018)... ... ... On July 30, more than 250 people attended Calvary Hospital’s 30th annual Golf ... County. The event raised over $300,000 for Calvary programs and services for patients and ... by mentalist and comedian Eric Dittelman, a live auction, silent auction and raffle prizes ...
(Date:8/14/2018)... Calif. (PRWEB) , ... August 14, 2018 , ... ... leading dental support organizations (DSO) with nearly 400 affiliated offices across 16 states, ... Orthodontics in San Diego, California. , Smile Brands will provide full-service administrative ...
(Date:8/11/2018)... OVERLAND PARK, Kan. (PRWEB) , ... August 10, ... ... Gout Gone, an industry leader in Gout Relief. , What is gout? This ... the lower extremities as a result of high levels of uric acid. Other ...
Breaking Medicine News(10 mins):
(Date:8/11/2018)... , ... August 11, 2018 , ... ... on Monday, August 13, with fun, games and gifts. Left-Handers are possibly the ... designed for right-handers. Having endured centuries of prejudice, countless indignities and inconveniences, left-handers ...
(Date:8/9/2018)... ... ... Doctor Snehal Patel is offering the residents of South Fairfax County and Prince ... who are in need of full-arch restorations, but who otherwise couldn’t afford it, are ... , "Our local communities have been very good to us and we want to ...
(Date:8/7/2018)... , ... August 07, 2018 ... ... the appointment of Richard A. Stark to assume the role of Sanarus Technologies President, effective ... 20+ years of strategic development, marketing and sales experience in medical device toward finding ...
Breaking Medicine Technology: